Emcure, Italy’s WiQo Tie Up to Launch Skin-Tightening Product in India

Emcutix Biopharmaceuticals Ltd., a wholly owned subsidiary of Emcure Pharmaceuticals, has signed an exclusive in-licensing agreement with Italy-based derma-cosmetic and medical device company WiQo. The partnership grants Emcutix the rights to import, market, distribute, and sell WiQo’s skin-tightening product, PRX-PLUS, in India.

As of 9:53 AM on April 2, Emcure Pharmaceuticals share price was trading at ₹1071.25, with a 13.03% gain over the past month and a 26.33% decline over the past six months.

Product Details

PRX-PLUS is a topical, non-invasive aesthetic solution used for skin tightening. The product does not require injections and is positioned as an alternative to traditional skin treatments. It is described as a 15-minute in-clinic procedure that offers immediate results without downtime. It is suitable for all skin types, phototypes and can be used year-round.

As per the filing, the formulation includes TCA salts and is adapted specifically for the APAC region. Since its introduction, over 8 million procedures using PRX-PLUS and related technologies have been performed globally. More than 40,000 dermatologists and aesthetic doctors worldwide use WiQo’s patented products.

Market Context

According to data from the reports, the dermatology segment in India is currently valued at approximately USD 1.8 billion. The sector has been growing at a rate of 11-12%, driven by rising awareness of skincare and increased consumer spending in the category.

Company Backgrounds

Emcutix was established in 2024 to focus on both prescription and consumer dermatology solutions in India. WiQo, founded in 1994 in Italy, specialises in non-surgical skin health devices and was acquired by ARCHIMED in 2023 to support its global expansion.

Conclusion

The agreement marks the introduction of PRX-PLUS to the Indian aesthetic dermatology market amid a period of sector growth and rising demand for non-invasive skin treatments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.